Twist Bioscience Corporation (TWST) Confirms Settlement with Agilent (A)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Twist Bioscience Corporation (TWST) Misses Q1 EPS by 86c, Revenues Beat; Offers FY20 Revenue Mid-Point Guidance Below Consensus
February 6, 2020 4:45 PM ESTTwist Bioscience Corporation (NASDAQ: TWST) reported Q1 EPS of ($1.69), $0.86 worse than the analyst estimate of ($0.83). Revenue for the quarter came in at $17.16 million versus the consensus estimate of $16.07 million.
FISCAL 2020 FIRST QUARTER FINANCIAL RESULTS
Orders: Total orders received for the first quarter of fiscal 2020 were $24.8 million, compared to $15.2 million for the same period of fiscal 2019.Revenue: Total revenues were $17.2 million for the first quarter of fiscal 2020 compared to $11.5 million for the same period of fiscal 2019.Cost of Revenues: Cost of revenues for the first quarter of fiscal 2020 was $13.8 million... More